This is an open label Comparative Effectiveness Research (CER) study in which patients will be randomized at the site level to Prospera surveillance or EMB surveillance in a 2:1 ratio (Prospera to EMB) at each site.
Subjects will be enrolled into the study while under evaluation…
Phase: NA • Sponsor: Natera, Inc.
Last updated Mar 02, 2026 15:24 UTC